期刊文献+

巴洛沙星片治疗急性泌尿系统感染105例的随机对照研究 被引量:6

A randomized and comparative control clinical study of balofloxacin tablets for treatment of 214 patients with acute urinary tract infections
下载PDF
导出
摘要 目的:评价国产巴洛沙星治疗急性泌尿系统感染的有效性及安全性。方法:采用多中心、随机、双盲、阳性药物平行对照研究方法。214例急性泌尿系统感染病人随机分为2组。试验组(n=105)男性22例,女性83例,年龄(40±s 14)a;对照组(n=109)男性20例,女性89例,年龄(39±12)a。试验组予巴洛沙星100 mg,对照组予左氧氟沙星100 mg,均口服,bid,疗程5~14 d。观察2组治疗前后症状、体征、尿常规、尿细菌培养等的变化。结果:试验组和对照组总治愈率、有效率分别为77.1%、96.2%和81.8%、97.3%,2组差异无显著意义(P>0.05)。2组细菌清除率为95%和94%,无显著差异(P>0.05)。2组不良反应发生率为8.2%和8.9%(P>0.05),主要表现为恶心、腹泻和转氨酶暂时性升高。结论:国产巴洛沙星可有效治疗急性泌尿系统感染。 AIM: To evaluate the efficacy and safety of domestic balofloxacin tablets in the treatment of acute bacterial urinary tract infections. METHODS: A randomized and comparative control clinical study recruited from 214 patients with urinary tract infections dividing into 2 groups randomly; 105 patients (M 22, F 83, age (40 ± s 14) a) with balofloxacin 100 mg bid orally in the trial group and 109 patients (M 20, F 89, age (39 ± 12) a) with levofloxacin 100 mg bid orally in the control group, were under a course of 5 to 14 days. Symptoms, signs, urinary routine test and urinary germiculture were undertaken and compared before and after treatment for both groups. RESULTS: The totle cure rates and effective rates of trial and control group were 77.1% vs 96.2 % and 81.8 % vs 97.3 %; the bacterial eradication rates were 95 % vs 94 %, respectively; for the trial and control group showing no significant difference (P 〉 0.05) . The incidence of adverse reactions was 8.2 % vs 8.9 % (P 〉 0.05) for both groups, including nausea, vomiting, diarrhea and transient elevated transaminases. CONCLUSION: Domestic balofloxacin is effective for the treatment of acute urinary tract infections.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2007年第9期653-656,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 巴洛沙星 左氧氟沙星 细菌感染 泌尿道感染 balofloxacin levofloxacin bacterial infections urinary tract infections
  • 相关文献

参考文献9

  • 1ALKSNE L.Balofloxacin choongwae[J].Curr Opin Investig Drugs,2003,4(2):224-229.
  • 2廖斌,丛欣,廖清江.2002年世界上市的新药[J].药学进展,2003,27(3):190-192. 被引量:17
  • 3王永利.人工合成抗菌药[M]//杨世杰.药理学.北京:人民卫生出版社,2001:88-89.
  • 4袁喆,肖永红,张唯力,王长征,金欢胜.加替沙星与左氧氟沙星随机双盲对照治疗泌尿系统感染98例[J].中国新药与临床杂志,2004,23(11):753-757. 被引量:16
  • 5KOZAWAO,UEMATSU T,MATSUNO H,et al.Comparative study of pharmacokinetics of two new fluoroquinolones,balofloxacin and grepafloxacin,in elderly subjects[J].Antimicrob Agents Chemother,1996,40(12):2824-2828.
  • 6糜志远,刘万忠.新氟喹诺酮类抗生素巴洛沙星研究进展[J].中国新药杂志,2005,14(9):1205-1210. 被引量:21
  • 7IWASAKI H,MIYAZAKI S,TSUJI A,et al.In vitro and in vivo antibacterial activities of Q-35,a novel fluoroquinolone[J].Chemotherapy,1995,41(2):100-112.
  • 8KAWAHARA S,TADA A,NAGARE H.In vitro antimycobacterial activities of a new quinolone,balofloxacin[J].Kekkaku,2001,76(1):29-31.
  • 9RUBINESTEIN E.History of quinolones and their side effects[J].Chemotherapy,2001,47 Suppl 3:3-8.

二级参考文献26

  • 1[1]Pharma Mar ket letter, 2003,30 (6): 24 - 25.
  • 2[2]Scrip, 2003,No2823:26.
  • 3Alksne L. Balofloxacin choongwae[J]. Curt Opin Investig Drugs,2003,4(2) : 224 - 229.
  • 4Ochi. K. Process for producing quinolonecarboxylic acid derivative[ P] . EP,0641782A1 , 1992 - 07 - 15.
  • 5Takagi N, Fubasami H, Matsukubo H. (6,7)-substituted-8-aikoxy-1-cyclo-propyl-1, 4ihydro-4-oxo-3-quinoline-carboxylic acid-( 03,04)-bis(acyloxy-0) borate and the salt thereof, and the preparing method of the same[P]. USP,5157117, 1992- 10- 20.
  • 6Nagano H, Yokota T, Katoh Y. Novel quinolonecarboxylic acid derrivatives[ P]. USP,5051509,1991 - 09 - 24.
  • 7永野洋幸,横田 健,加藤保幸.新规キノロソカルボソ酸誘導体[P].平3—95117,1991—04—19.
  • 8Kojima K, Ito T, Munemura K, et al. In vitro antibacterial activity of balofloxacin[J]. Jpn J Chemother, 1995,43 (S5) : S60 - S76.
  • 9Kojima K, Ito T, Munemura K, et al. In vivo antibacterial activity of balofloxacin[J]. Jpn J Chemother, 1995,43(S5) :S77 - S83.
  • 10Ito T, Kojima K, Koizumi K, et al. Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structureactivity relationship of Q-35 analogs[J]. Biol Pharm Bull, 1994,17(7) : 927 - 930.

共引文献50

同被引文献33

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部